Chemical industry – Page 105
-
Opinion
A notable year for closures and layoffs
It's been a rough year, but the future looks bright, says Derek Lowe
-
Business
Business roundup: January 2008
Manufacturing chemists face worldwide job cuts Bristol-Myers Squibb (BMS) has become the latest pharmaceutical company to announce a cost-saving restructuring plan that will slash manufacturing jobs. The US drug maker will scale down in its manufacturing operations, cutting its workforce by 4800 - about 10 per cent - ...
-
Business
Business roundup: December 2007
Price fight over HIV drug GlaxoSmithKline has filed a lawsuit against Abbott Laboratories, claiming that its 2003 decision to increase the price of its HIV drug Norvir by 400 per cent was anticompetitive. GSK is the latest in a growing list of claimants to sue its US competitor, including four ...
-
Business
Business roundup: November 2007
Drug marketing case sees $500m settlement Bristol-Myers Squibb will pay over half a billion dollars to settle allegations of illegal drug marketing and pricing. The ruling, announced by the US Department of justice in late September, related to accusations that BMS had inflated its drug prices, paid kickbacks ...
-
Opinion
The hidden benefit of higher energy bills
The high cost of energy has an unexpected benefit, says Derek Lowe - it forces us to be more efficient
-
Business
Business roundup: October 2007
UK pharma shifts manufacturing overseas Anglo-Swedish drug firm AstraZeneca has restated its intention to outsource drug manufacturing ’where there is a sound business case’. The statement follows the publication of an interview with David Smith, AstraZeneca’s executive vice-president of operations, in The Times on 17 September. The newspaper ...
-
Opinion
Zero justification
Will Phase Zero trials actually help drug development, wonders Derek Lowe
-
Opinion
Credit where it's due
Process chemists just don't get the credit they deserve, says Derek Lowe
-
Business
Business roundup: September 2007
ICI sale finally agreed ICI have accepted a takeover offer of £8 billion from chemical conglomerate Akzo Nobel. This 670p per share agreement is Akzo’s third approach for ICI in as many months, following an initial offer of 600p per share in June, and then 650p per share in ...
-
Opinion
Blinkers for bad news
The Avandia controversy poses some tough questions about how to balance risks, says Derek Lowe
-
Business
Business roundup: July 2007
A depressing ruling for obesity drug A decision by a US Food and Drug Administration (FDA) advisory panel on 13 June was a double blow for French drug firm, Sanofi-Aventis. Their long-awaited obesity drug, rimonabant, marketed in Europe as Acomplia, was not recommended for approval by the FDA. ...
-
Opinion
Patented fundamentals
Derek Lowe sets the record straight about pharmaceutical patents on traditional medicines
-
Business
Business roundup: June 2007
FDA powers boosted by Senate Bill The US Senate has passed legislation to reinforce the authority of the Food and Drug Administration (FDA) to regulate drugs and medical devices. Under the legislation, there will be an increase in user fees that drugs companies and makers of medical devices ...
-
Business
Business roundup: May 2007
US chemical plant security legislation The US Department of Homeland Security (DHS) has released its final list of federal security regulations governing US chemical plants. The 2001 terrorist attacks in New York brought security measures under scrutiny, but with America on high alert many felt that chemical ...
-
Opinion
Reasons to be cheerful
After months of bleak news about faltering pipelines and redundancies, it's time to find reasons to be cheerful about the drug industry, says Derek Lowe.
-
Opinion
Justifying total synthesis
Derek Lowe wonders whether total synthesis is still worth the effort
-
Business
Business roundup: April 2007
Pharma’s house of cards Anglo-Swedish drug company AstraZeneca has announced plans to cut roughly 700 jobs at its site in Macclesfield, UK. A further 850 staff will go at Swedish production facilities. The news marks the first step in the implementation of the company’s plans to cut 3000 jobs from ...
-
Opinion
Mergers: a cost-benefit analysis
Do the benefits of pharmaceutical company mergers really outweigh the costs, asks Derek Lowe